TY - JOUR
T1 - The role of DNA repair in chronic lymphocytic leukemia pathogenesis and chemotherapy resistance
AU - Sampath, Deepa
AU - Plunkett, William
PY - 2007/9
Y1 - 2007/9
N2 - Front-line therapy for chronic lymphocytic leukemia (CLL) with alkylating agents is associated with low rates of complete remission and no improvement in overall survival. The ability of CLL cells to efficiently repair alkylator-induced damage to DNA might explain this lack of response. Novel strategies that inhibit DNA repair, such as combinations of alkylating agents, purine nucleoside analogues, and immunotherapy, have produced durable clinical and molecular remission in both untreated and relapsed CLL. This review evaluates the contribution of DNA repair processes in the development of resistance to chemotherapy and the impact of therapies that exploit the DNA repair capacity of CLL cells to therapeutic advantage.
AB - Front-line therapy for chronic lymphocytic leukemia (CLL) with alkylating agents is associated with low rates of complete remission and no improvement in overall survival. The ability of CLL cells to efficiently repair alkylator-induced damage to DNA might explain this lack of response. Novel strategies that inhibit DNA repair, such as combinations of alkylating agents, purine nucleoside analogues, and immunotherapy, have produced durable clinical and molecular remission in both untreated and relapsed CLL. This review evaluates the contribution of DNA repair processes in the development of resistance to chemotherapy and the impact of therapies that exploit the DNA repair capacity of CLL cells to therapeutic advantage.
UR - http://www.scopus.com/inward/record.url?scp=34548485558&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=34548485558&partnerID=8YFLogxK
U2 - 10.1007/s11912-007-0048-6
DO - 10.1007/s11912-007-0048-6
M3 - Review article
C2 - 17706164
AN - SCOPUS:34548485558
SN - 1523-3790
VL - 9
SP - 361
EP - 367
JO - Current oncology reports
JF - Current oncology reports
IS - 5
ER -